Allan S G, Hay F G, McIntyre M A, Leonard R C
Imperial Cancer Research Fund, University Department of Clinical Oncology, Western General Hospital, Edinburgh, UK.
Br J Cancer. 1987 Oct;56(4):485-8. doi: 10.1038/bjc.1987.229.
Forty fixed tissue sections from patients with small cell lung carcinoma (SCCL) have been stained with a panel of 10 monoclonal antibodies using a peroxidase anti-peroxidase method and the incidence of staining has been compared to patient characteristics at presentation and to survival. An inverse association between HMFG2 staining and survival was found with median survival in HMFG2 negative patients 13 months compared to 8 months for HMFG2 positive patients. No such association was found with the other antibodies and no association was found between staining and disease extent or primary versus secondary deposits with this panel of antibodies. Epidermal growth factor receptor was detected in 3/38 presentation biopsies and in these 3 patients mean survival was only 5 months. Further prospective study of HMFG2 as a prognostic indicator in SCCL is suggested.
采用过氧化物酶抗过氧化物酶法，用一组10种单克隆抗体对40例小细胞肺癌（SCCL）患者的固定组织切片进行染色，并将染色发生率与患者就诊时的特征及生存率进行比较。发现HMFG2染色与生存率呈负相关，HMFG2阴性患者的中位生存期为13个月，而HMFG2阳性患者为8个月。其他抗体未发现此类关联，且该组抗体的染色与疾病范围或原发性与继发性沉积物之间也未发现关联。在38例就诊时的活检中检测到3例表皮生长因子受体，这3例患者的平均生存期仅为5个月。建议对HMFG2作为SCCL预后指标进行进一步的前瞻性研究。
